Frank Frantzen
Chief Tech/Sci/R&D Officer at CardiNor AS
Profile
Frank Frantzen is currently the Chief Technology Officer at CardiNor AS.
Prior to this, he worked as the Senior Director of Research and Development at Abbott Norge AS and as a Director at Gentian Diagnostics ASA. Frantzen holds a graduate and doctorate degree from the Norwegian University of Science & Technology.
Frank Frantzen active positions
| Companies | Position | Start |
|---|---|---|
CardiNor AS
 CardiNor AS BiotechnologyHealth Technology CardiNor AS develops, produces, and sells in-vitro diagnostic products. It establishes a blood test for elevated levels of Secretoneurin that may indicate that a patient has a heart disease. The company was founded on June 25, 2015 and is headquartered in Oslo, Norway. | Chief Tech/Sci/R&D Officer | - |
Former positions of Frank Frantzen
| Companies | Position | End |
|---|---|---|
| GENTIAN DIAGNOSTICS | Director/Board Member | 17/12/2023 |
Abbott Norge AS
 Abbott Norge AS Pharmaceuticals: MajorHealth Technology Abbott Norge AS researches, markets, and trades pharmaceuticals and laboratory diagnostics. The company was founded on March 12, 1990 and is headquartered in Fornebu, Norway. | Chief Tech/Sci/R&D Officer | 31/12/2020 |
Training of Frank Frantzen
| Norwegian University of Science & Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GENTIAN DIAGNOSTICS | Health Technology |
| Private companies | 2 |
|---|---|
Abbott Norge AS
Abbott Norge AS Pharmaceuticals: MajorHealth Technology Abbott Norge AS researches, markets, and trades pharmaceuticals and laboratory diagnostics. The company was founded on March 12, 1990 and is headquartered in Fornebu, Norway. | Health Technology |
CardiNor AS
CardiNor AS BiotechnologyHealth Technology CardiNor AS develops, produces, and sells in-vitro diagnostic products. It establishes a blood test for elevated levels of Secretoneurin that may indicate that a patient has a heart disease. The company was founded on June 25, 2015 and is headquartered in Oslo, Norway. | Health Technology |
- Stock Market
- Insiders
- Frank Frantzen
